Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The settlement provides for a fund of $3,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement

Humanigen (OTCMKTS: HGEN ) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This bankruptcy filing comes after Humanigen failed to secure regulatory approval for its Covid-19 treatment lenzilumab.

HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy

Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.

COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy

The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host Disease Planned interim assessment expected in 2024 following treatment of first 20 participants Short Hills, New Jersey--(Newsfile Corp. - August 7, 2023) - Humanigen, Inc. (OTC Pink: HGEN), a clinical-stage biopharmaceutical company, today announced successful dosing of the first participant in the RATinG trial of lenzilumab for the early treatment of acute Graft versus Host Disease (aGvHD), conducted by IMPACT, a world-class accelerated clinical trial network delivering innovative research for stem cell transplant patients in major centers in the UK. "I am delighted that we have treated our first patient and am grateful to the IMPACT Partnership, Humanigen and to the US MAGIC Consortium for supporting this important study," said Professor Adrian Bloor MA, MB BChir, PhD, FRCP, FRCPath, director of Stem Cell Transplantation, The Christie NHS Foundation Trust.

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

Humanigen Inc shares have plummeted more than 90% over the past month, and now trades at a little over a penny per share, after the clinical-stage biopharmaceutical company said it is facing bankruptcy after negotiations for a reverse merger with an unnamed, privately-held biopharma company ended.   Humanigen noted that it is unable to find another source of financing that would allow it to maintain its Nasdaq listing, including a minimum share price of $1, and it is now trading on OTC Pink Market.

Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy

Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements. According to a filing from the company, it is no longer compliant with Nasdaq listing standards.

Why Is Humanigen (HGEN) Stock Down 72% Today?

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durable CMML is a rare, aggressive cancer; approximately 20% of patients survive three years from diagnosis No new CMML medications with novel mechanisms of action have been approved in over 30 years and hypomethylating agents, such as azacitidine alone, are currently considered "standard of care" Short Hills, New Jersey--(Newsfile Corp. - June 9, 2023) - Humanigen, Inc. (Nasdaq: HGEN) today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations. The additional data demonstrate that in all 10 participants with at least three months of treatment with both lenzilumab and azacitidine, blood monocyte count decreased fivefold (P=0.03), the percentage of blast cells and pro-monocytes decreased more than twofold (P=0.04), and C-reactive protein decreased more than threefold (P=NS) with improvements noted after both 3 months and 6 months of this combination treatment.

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

Eightco Holdings Inc

Ohmyhome Ltd

Best penny stocks to buy now? 3 to watch in the stock market today.

3 Hot Penny Stocks To Watch Today; Is It Time To Buy?

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine Six evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-up Lenzilumab appears to be well-tolerated Short Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomonocytic Leukemia (PREACH-M) study of lenzilumab in chronic myelomonocytic leukemia (CMML), at the 2023 annual meeting of the American Association of Cancer Research being held in Orlando, FL April 14-19. PREACH-M is currently treating 11 intermediate and high risk CMML subjects (five male, six female; mean age 68 years) with lenzilumab, a granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody, and azacitidine, the current standard of care for CMML.

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

The Beachbody Co.

Carvana

Excelerate Energy Inc

Enviva Partners

Hillman Solutions Corp

Ivanhoe Electric Inc / US

Dave & Buster's

B. Riley Financial

Fintel's Officer Sentiment quant model identifies companies that experienced significant officer buying activity in the last year.

10 Stocks That Experienced Significant Officer Buying Activity Over 2022

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy.

Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr.

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

The stock price of Humanigen (HGEN) increased 19.91% in the most recent trading session. This is why.

Humanigen (HGEN) Stock Increased 19.91%: Details

Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options.

Humanigen Announces Retention of SC&H Capital as Financial Advisor

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging that the Company violated federal securities laws. Class Period: May 16, 2020 to July 12, 2022 Lead Plaintiff Deadline: October 25, 2022 No obligation or cost to you.

HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders

Akero Therapeutics Inc

Astria Therapeutics

HeartBeam

ContraFect

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

New York, New York--(Newsfile Corp. - October 24, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit.The lawsuit on behalf of Humanigen investors has been commenced in the the United States District Court for the District of New Jersey. Affected investors purchased or otherwise acquired certain Humanigen, Inc. securities between May 16, 2020 and July 12, 2022.

HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16, 2020 and July 12, 2022, both dates inclusive (the "Class Period") of the important October 25, 2022 lead plaintiff deadline. SO WHAT: If you purchased Humanigen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

HGEN DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Attention Humanigen, Inc. ("Humanigen") (NASDAQ: HGEN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 16, 2020 and July 12, 2022. If you suffered a loss on your investment in Humanigen, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Humanigen Investors of a Lead Plaintiff Deadline of October 25, 2022

New York, New York--(Newsfile Corp. - October 23, 2022) - Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit.The lawsuit on behalf of Humanigen investors has been commenced in the the United States District Court for the District of New Jersey. Affected investors purchased or otherwise acquired certain Humanigen, Inc. securities between May 16, 2020 and July 12, 2022.

Humanigen Class Action: Levi & Korsinsky Reminds Humanigen, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 25, 2022 - HGEN

New York, New York--(Newsfile Corp. - October 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16, 2020 and July 12, 2022, both dates inclusive (the "Class Period") of the important October 25, 2022 lead plaintiff deadline.

HGEN FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN

NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/humanigen-inc-loss-submission-form/?id=32774&from=4 The lawsuit seeks to recover losses for shareholders who purchased Humanigen between May 16, 2020 and July 12, 2022.

HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022

Did you lose money on investments in Humanigen? If so, please visit Humanigen, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.New York, New York--(Newsfile Corp.

HUMANIGEN, INC. (HGEN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Humanigen, Inc. (HGEN)

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)

News for Humanigen Stock (HGEN)